However, its potential benefits in improving cardiovascular (CV) risk factors have yet to be determined
Before propensity score matching, the semaglutide or tirzepatide cohort and other GLP-1RA cohorts included 82 972 and 124 908 patients, respectively
Weight management is not one-size-fits-all
Doctors who Science News talked to for this story emphasized the significance of the recent MASH progress, calling this era in the field a watershed moment, and the more than a dozen new medications in development a tidal wave. Rezdiffra may have been the first drug FDA-approved for MASH, but in the next two to three years, Su says, there will be many more
Design : This was a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial for 72 weeks that included patients with biopsy confirmed NASH and hepatic fibrosis (stage F1, F2, or F3 but not F4/cirrhosis)